SYBLEU INC. intends to engage in the primarily in the acquisition, licensing, and development of regenerative medical applications. It develops medical applications up to the point of completion of Phase I and or Phase II clinical trials after which the company sell or license developed applications or advance the application to Phase III clinical trials. SYBLEU INC. was incorporated in 2020 and i...
Sybleu reported revenue of $11,696 for fiscal year 2023, about flat from fiscal year 2022, and net income of -$180,304. In Q2 2024 (the quarter ended December 31, 2023) revenue was $2,949, about flat from a year before. Its market capitalization was $583,742 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended June 30, 2023; market data as of October 8, 2026.
No profile data available.